Core Viewpoint - The company anticipates a significant net loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -288 million to -380 million yuan, indicating a continuation of losses compared to the previous year [1][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -295 million to -387 million yuan [3]. Group 2: Previous Year’s Performance - In the previous year, the total profit was -85.43 million yuan, with a net profit attributable to shareholders of -86.69 million yuan [5]. - The net profit attributable to shareholders, after excluding non-recurring gains and losses, was -94.33 million yuan [5]. - The earnings per share for the previous year were -0.0512 yuan [6]. Group 3: Reasons for Expected Loss - The medical services segment is experiencing losses due to high fixed costs and low gross margins from drug and consumable sales, despite a revenue increase of approximately 60% compared to the previous year [7]. - The coal business is facing losses due to reduced effective mining time and increased costs, alongside a decline in coal sales prices [7]. - The chemical business is impacted by reduced production and increased maintenance costs due to a major overhaul in 2025, leading to decreased net profit [7]. Group 4: Non-Operating Gains and Losses - The non-operating gains and losses for the reporting period include government subsidies and other net income of 3.4879 million yuan [8]. Group 5: Additional Notes - The performance forecast data is preliminary and has not been audited by registered accountants; the final figures will be disclosed in the audited annual report for 2025 [4][10].
贵州赤天化股份有限公司2025年年度业绩预亏公告